The pilot and feasibility (P&F) grant program represents an extremely valuable and effective opportunity for the Vanderbilt O'Brien Kidney Center to provide funds for the support of kidney disease related projects. Funding for the P&F program started in 2002 during a previous funding cycle for the O'Brien centers (2002-2007) and continued through the P30 Vanderbilt O'Brien Kidney Center (2008-2013). For this competitive application, the goal of the program continues to be to support i) small research projects by new investigators with little or no independent research support; ii) established investigators who are turning to kidney-related research for the first time; or iii) established investigators in kidney related research who are undertaking a strikingly new research direction. Applicants must hold a faculty appointment (Instructor or above) to submit a P&F proposal, and must meet the NIH Eligibility Guidelines for P&F support. In our previous funding cycles (2002-2013), the Vanderbilt O'Brien Kidney Center funded 19 applications, from a total of 53 applications. Summaries of the funded applications are detailed below. For this application, we are requesting funding for 9 applications for years 2017-2022, all of which will meet the guidelines of our P&F program and will extensively utilize our proposed biomedical cores.

Public Health Relevance

The pilot and feasibility (P&F) grant program represents an extremely valuable and effective opportunity for the Vanderbilt O'Brien Kidney Center (VOKC) to provide funds for the support of kidney disease related projects. We will support small research projects by new investigators with little or no independent research support who are turning to kidney-related research for the first time; support established investigators, primarily interested in models of kidney disease to undertake a strikingly new research direction; and allow investigators to conduct pilot studies using the facilities of the VOKC as well as the tools and reagents available through the Cores.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK114809-03
Application #
9734064
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
3
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
079917897
City
Nashville
State
TN
Country
United States
Zip Code
37232
Chung, Sungjin; Overstreet, Jessica M; Li, Yan et al. (2018) TGF-? promotes fibrosis after severe acute kidney injury by enhancing renal macrophage infiltration. JCI Insight 3:
Wang, Feng; Katagiri, Daisuke; Li, Ke et al. (2018) Assessment of renal fibrosis in murine diabetic nephropathy using quantitative magnetization transfer MRI. Magn Reson Med 80:2655-2669
Li, Yan; Chung, Sungjin; Li, Zhilian et al. (2018) Fatty acid receptor modulator PBI-4050 inhibits kidney fibrosis and improves glycemic control. JCI Insight 3:
Wang, Feng; Takahashi, Keiko; Li, Hua et al. (2018) Assessment of unilateral ureter obstruction with multi-parametric MRI. Magn Reson Med 79:2216-2227
Zhang, Ming-Zhi; Wang, Suwan; Wang, Yinqiu et al. (2018) Renal Medullary Interstitial COX-2 (Cyclooxygenase-2) Is Essential in Preventing Salt-Sensitive Hypertension and Maintaining Renal Inner Medulla/Papilla Structural Integrity. Hypertension 72:1172-1179
Zhu, Lin; Luu, Thao; Emfinger, Christopher H et al. (2018) CETP Inhibition Improves HDL Function but Leads to Fatty Liver and Insulin Resistance in CETP-Expressing Transgenic Mice on a High-Fat Diet. Diabetes 67:2494-2506
Borza, Corina M; Pozzi, Ambra; Plosa, Erin J (2018) Discoidin Domain Receptor 2, a Potential Therapeutic Target in Lung Fibrosis. Am J Respir Cell Mol Biol 59:277-278
Lim, Beom Jin; Yang, Jae Won; Zou, Jun et al. (2017) Tubulointerstitial fibrosis can sensitize the kidney to subsequent glomerular injury. Kidney Int 92:1395-1403